Compugen Concentrates On Pipeline After AZ Antibody Pact

 
• By Kevin Grogan

It is nearly five years since Compugen signed a deal with Bayer but with AstraZeneca paying $10m up front for a license to develop bispecific and multi-specific antibody products derived from its pipeline, the Tel Aviv-headquartered biotech's computational discovery approach has been validated.

Welding
Checking the pipeline: Compugen is getting close to the clinic • Source: Shutterstock

More from Immuno-oncology

More from Anticancer